Jimenez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Moreno S, Nogales A, Ortego J
Microorganisms. 2020; 9(1).
PMID: 33375723
PMC: 7823852.
DOI: 10.3390/microorganisms9010042.
Mohl B, Kerviel A, Labadie T, Matsuo E, Roy P
Viruses. 2020; 12(3).
PMID: 32245145
PMC: 7150864.
DOI: 10.3390/v12030343.
Mohl B, Roy P
J Virol. 2019; 93(20).
PMID: 31375577
PMC: 6798104.
DOI: 10.1128/JVI.00898-19.
Matsuo E, Yamazaki K, Tsuruta H, Roy P
J Virol. 2017; 92(3).
PMID: 29142128
PMC: 5774872.
DOI: 10.1128/JVI.01784-17.
Celma C, Stewart M, Wernike K, Eschbaumer M, Gonzalez-Molleda L, Breard E
J Virol. 2016; 91(1).
PMID: 27795442
PMC: 5165199.
DOI: 10.1128/JVI.01892-16.
Purification of infective bluetongue virus particles by immuno-affinity chromatography using anti-core antibody.
Chand K, Biswas S, Mondal B
Virusdisease. 2016; 27(1):98-101.
PMID: 26925450
PMC: 4758307.
DOI: 10.1007/s13337-015-0298-0.
Development of reverse genetics for Ibaraki virus to produce viable VP6-tagged IBAV.
Matsuo E, Saeki K, Roy P, Kawano J
FEBS Open Bio. 2015; 5:445-53.
PMID: 26101741
PMC: 4472822.
DOI: 10.1016/j.fob.2015.05.006.
Structure based modification of Bluetongue virus helicase protein VP6 to produce a viable VP6-truncated BTV.
Matsuo E, Leon E, Matthews S, Roy P
Biochem Biophys Res Commun. 2014; 451(4):603-8.
PMID: 25128829
PMC: 4169673.
DOI: 10.1016/j.bbrc.2014.08.028.
Continuity of the dsRNA genome of bluetongue virus.
Foster N, Alders M, Walton T
Curr Microbiol. 2013; 1(3):171-4.
PMID: 23338144
DOI: 10.1007/BF02601672.
Minimum requirements for bluetongue virus primary replication in vivo.
Matsuo E, Roy P
J Virol. 2012; 87(2):882-9.
PMID: 23115294
PMC: 3554043.
DOI: 10.1128/JVI.02363-12.
Bluetongue virus non-structural protein 1 is a positive regulator of viral protein synthesis.
Boyce M, Celma C, Roy P
Virol J. 2012; 9:178.
PMID: 22931514
PMC: 3479040.
DOI: 10.1186/1743-422X-9-178.
Bluetongue virus VP1 polymerase activity in vitro: template dependency, dinucleotide priming and cap dependency.
Matsuo E, Roy P
PLoS One. 2011; 6(11):e27702.
PMID: 22110731
PMC: 3216989.
DOI: 10.1371/journal.pone.0027702.
Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.
Matsuo E, Celma C, Boyce M, Viarouge C, Sailleau C, Dubois E
J Virol. 2011; 85(19):10213-21.
PMID: 21795358
PMC: 3196398.
DOI: 10.1128/JVI.05412-11.
Bluetongue virus VP6 acts early in the replication cycle and can form the basis of chimeric virus formation.
Matsuo E, Roy P
J Virol. 2009; 83(17):8842-8.
PMID: 19553329
PMC: 2738189.
DOI: 10.1128/JVI.00465-09.
Changes of the abundance of Culicoides obsoletus s.s. and Culicoides scoticus in Southwest Germany identified by a PCR-based differentiation.
Balczun C, Vorsprach B, Meiser C, Schaub G
Parasitol Res. 2009; 105(2):345-9.
PMID: 19319570
DOI: 10.1007/s00436-009-1412-2.
Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts.
Boyce M, Celma C, Roy P
J Virol. 2008; 82(17):8339-48.
PMID: 18562540
PMC: 2519640.
DOI: 10.1128/JVI.00808-08.
Recovery of infectious bluetongue virus from RNA.
Boyce M, Roy P
J Virol. 2006; 81(5):2179-86.
PMID: 17151117
PMC: 1865916.
DOI: 10.1128/JVI.01819-06.
The pathogenesis of bluetongue virus infection of bovine blood cells in vitro: ultrastructural characterization.
BREWER A, MacLachlan N
Arch Virol. 1994; 136(3-4):287-98.
PMID: 8031234
DOI: 10.1007/BF01321058.
Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances.
Smee D, Sidwell R, Clark S, Barnett B, Spendlove R
Antimicrob Agents Chemother. 1981; 20(4):533-8.
PMID: 6282197
PMC: 181738.
DOI: 10.1128/AAC.20.4.533.
Bluetongue virus hemagglutination and its inhibition by specific sera.
Hubschle O
Arch Virol. 1980; 64(2):133-40.
PMID: 6247995
DOI: 10.1007/BF01318017.
